BK Virus (BKV) Infection Market is segmented By Treatment (RNA Interference-based Therapy, Givosiran, Symptomatic Treatment), By Distribution Channel (Hospital Pharmacies ....
Market Size in USD
CAGR41.7%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 41.7% |
Market Concentration | High |
Major Players | AlloVir, Amplyx Pharmaceuticals, SL VAXiGEN, Hybridize Therapeutics, Vera Therapeutics, Inc. |
The BK Virus (BKV) infection market is estimated to be valued at USD 34 Mn in 2024 and is expected to reach USD 389 Mn by 2031, growing at a compound annual growth rate (CAGR) of 41.7% from 2024 to 2031. The market is expected witness steady growth during the forecast period due to the rising prevalence of BKV infections among immunocompromised patients undergoing organ transplantation or receiving immunosuppressive therapy for autoimmune disorders.